A preeminent figure in nanotoxicology and pharmaceutical sciences, Dr. Emmanuel Eni Amadi (B.Pharm., MSc, PG.Dip, EMBA, PhD), has profoundly shaped the understanding of nanomaterial safety with transformative contributions for biomedical applications. With a Ph.D. in Medical Sciences (Nanotoxicology) from the University of Bradford, United Kingdom (2019), an Executive MBA (EMBA) from Lancaster University, and more than 25 years of interdisciplinary expertise. Dr. Amadi’s ground-breaking research, clinical excellence and tactical leadership have earned him international commendation, evidenced by notable awards, high-impact publications and worldwide speaking engagements.
Dr. Amadi’s landmark 2019 doctoral dissertation, published in Bradscholars, Google Scholars, and ResearchGate, represents the first human blood-based genotoxicity study of commercial graphene oxide (GO) nanoparticles (15-20 layers, 4-10% edge oxidation) in contrast to prior studies limited to cancer cell lines or lab-synthesised graphene oxide. His research utilised samples from patients with asthma, COPD, and lung cancer, enhancing their clinical relevance. By December 2024, the thesis had gathered 551downloads and 280 views across 20 countries, with its impact recognised by the Financial Times for its real-world significance. Commissioning advanced techniques, such as Dynamic Light Scattering, Scanning Electron Microscopy, and Comet Assay, Dr. Amadi characterised graphene oxide net-negative surface charge (-23 ± 2 mV) and agglomeration behaviour, elucidating their influence on cellular uptake and toxicity.
His research unveiled six novel mechanisms of GO-induced DNA damage: Oxidative stress via reactive oxygen species (ROS), direct DNA binding, inflammation-mediated damage, cell cycle dysregulation (CDKN1A/p21), mitochondrial dysfunction, and epigenetic modifications (DNA methylation). These discoveries have redefined nanotoxicology, providing a strong framework for safer nanomaterials design. Dr. Amadi identified key biomarkers (like TP53, CDKN1A/p21, BCL-2) for predicting cancer susceptibility and developing targeted therapies for lung cancer diseases. His finding that peripheral blood leukocytes from lung cancer and COPD patients display greater sensitivity to GO-induced damage than those from asthma patients or healthy controls underscores the need for personalised nanomedicine and improved occupational safety standards.
Dr. Amadi’s contributions extend to clinical practice and leadership, as a senior Pharmacist and Training supervisor at Books UK Ltd, since February 2024, he oversees pharmaceutical operations and provides mentorship for over 10 junior staff, enhancing quality services. His exceptional performance secured a salary increase to nearly £65,000 within six months and £8,600 in sponsorship from Boots UK Ltd and NHS Education for Scotland for the Practice Certificate in Independent Prescribing at the University of Strathclyde. Unsolicited patient feedback, escalated by Boots UK’s Head Office, praised his “utmost care” and professionalism, affirming his clinical impact.
His leadership achievements are equally distinguished. As Founder of Amadi Global Ltd (2019–2024), Dr. Amadi generated over six figures in revenue, providing toxicology consultancy to the NHS and private sectors. His earlier venture, E. E. Amadi Ltd t/a Drugs4U Pharmacy, achieved over £1.2 million in revenue before its 2018 acquisition. As a Non-Executive Director at Oak Learning Partnership (2018–2020) in Bury, Greater Manchester, UK, he shaped the educational policy of the Multi-Academy Trust (MAT), and as a Graduate Teaching Assistant at the University of Bradford (2018–2021), he trained over 150 students in medical and pharmaceutical sciences. In 2017, as a visiting researcher at the National Institute of Health in Porto, Portugal, Dr. Amadi led a 15-member team to refine the Medium Throughput Alkaline Comet assay (MTACA), advancing genotoxicity research.
Dr. Amadi’s scholarly output includes five authored books on nanotoxicology, pharmaceutical sciences, and leadership, alongside peer-reviewed publications. His global influence is evidenced by invited talks at the 2019 NanoBoston World Conference, Boston, Massachusetts, USA; a guest speaker at the Fourth Scientific-Business International Conference – the InterNanoPoland 2019, held in Katowice, Poland, on October 16-17, 2019; Skegg School of Pharmacy, University of Montana, Montana, USA (2019), and several international conferences.
He is a recipient of several awards, including the Leverhulme Trade Charities Trust Doctoral Research Award (£14,120) and the 2017 EU COST ACTION Research Grant. “Dr. Amadi’s work is pivotal for safer nanotechnology,” notes Dr. João Paulo Fernandes Teixeira, his collaborator in Portugal.
In September 2024, Dr. Amadi was awarded the prestigious Best Paper Award by the International Journal of Health and Clinical Research (IJHCR) for his outstanding research contribution to the paper titled “Graphene Oxide Nanoparticles: A Genotoxic Risk for Patients with Lung Cancer, COPD and Asthma”. Published on July 31, 2024, in IJHCR (Volume 07, Issue 03, pp. 1–14), the study offered critical insights into the genotoxic implications of graphene oxide nanoparticles, particularly for patients with respiratory conditions—marking a significant advancement in the field of nanotoxicology.
In recognition of his exceptional scholarly impact and leadership in this emerging domain, Dr. Amadi was formally invited in October 2024 to join the Editorial Board of IJHCR, an international, peer-reviewed journal dedicated to promoting excellence in health sciences and clinical research. His appointment to the board underscores his reputation as a leading authority in the field. As an Editorial Board member, Dr. Amadi is entrusted with key responsibilities including reviewing scientific manuscripts, advising on editorial policies, and contributing to the journal’s strategic development.
These honours reflect Dr. Amadi’s sustained record of original scientific contributions, his influence on the global biomedical research community
As Dr. Amadi continues his research and prepares to become an independent prescriber from the University of Strathclyde, Glasgow, Scotland, UK, his work is shaping safer medical technologies and better healthcare systems. His unique blend of scientific brilliance, clinical care, and leadership makes him a transformative force in nanotoxicology and pharmaceutical sciences, with a legacy that promises to inspire and protect for years to come.
